BIO-TECHNE CORP shareholders Q3 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2022
NameSharesValueWeighting ↓
ARGUS INVESTORS' COUNSEL, INC. 4,211$1,196,0001.06%
Affiance Financial, LLC 6,258$1,777,0001.00%
ROWLANDMILLER & PARTNERS.ADV 13,070$3,711,880,0001.00%
Ascension Asset Management LLC 4,463$1,260,0000.99%
Dorsey & Whitney Trust CO LLC 32,509$9,232,0000.96%
Fluent Financial, LLC 6,155$1,748,0000.96%
Champlain Investment Partners, LLC 484,005$137,457,0000.94%
RIVERBRIDGE PARTNERS LLC 218,619$62,088,0000.92%
Values First Advisors, Inc. 4,488$1,274,0000.92%
Kensington Investment Counsel, LLC 3,716$1,055,0000.89%
Stephens Investment Management Group LLC 164,391$46,687,0000.88%
Sanchez Wealth Management Group 5,644$1,603,0000.88%
SANDLER CAPITAL MANAGEMENT 20,787$5,904,0000.82%
SEGALL BRYANT & HAMILL, LLC 239,542$68,035,0000.81%
Oak Thistle LLC 765$217,0000.78%
Legal Advantage Investments, Inc. 2,740$778,0000.73%
ROBERTS GLORE & CO INC /IL/ 7,048$2,002,0000.72%
FRED ALGER MANAGEMENT, LLC 444,510$126,241,0000.64%
ATLANTA CAPITAL MANAGEMENT CO L L C 472,491$134,187,0000.60%
Palisade Asset Management, LLC 14,196$4,032,0000.55%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2022. To view BIO-TECHNE CORP's shareholder history, click here.